On Jan. 27, 2020, the Centers for Medicare & Medicaid Services (CMS) expanded coverage of FDA-approved laboratory diagnostic tests that use next generation sequencing (NGS) for patients with germline, or inherited, ovarian or breast cancer. CMS also gave the Medicare Administrative Contractors (MACs) the ability to determine coverage of NGS laboratory tests for other inherited cancers.
Read CMS Decision Memo for NGS for Medicare Beneficiaries with Advanced Cancer (CAG-00450R).
Read CMS announcement.
Posted 1/28/2020
From mental health concerns to fertility preservation, adolescents and young adults with cancer require a specialized approach to treatment and survivorship care. In honor of Childhood Cancer Awareness Month, ACCC highlights a pivotal program from the University of North Carolina Lineberger Comprehensive Cancer Center and resources that meet the critical needs of these patients.
